Related Experiment Video
Updated: Aug 16, 2026

Identification of Rare Bacterial Pathogens by 16S rRNA Gene Sequencing and MALDI-TOF MS
Published on: July 11, 2016
Stenotrophomonas maltophilia infections
M Cecilia Dignani1, Monica Grazziutti, Elias Anaissie
1FUNDALEU, Buenos Aires, Argentina.
Abstract:
Stenotrophomonas maltophilia is a ubiquitous, gram-negative organism that causes hospital-acquired infections. Persons often come in contact with S. maltophilia through environmental water sources, including hospital tap water or faucets, and it has been associated with nosocomial outbreaks of infection. S. maltophilia often infects debilitated persons and those with underlying medical conditions, including immunosuppression. Manifestations of infection include pneumonia, often in mechanically ventilated patients, bacteremia, skin and soft tissue infection, urinary tract infection, and endocarditis. Treatment of S. maltophilia infection is difficult because the organism is resistant to a number of agents typically used for hospital-acquired infections. In vitro and clinical data indicate that trimethoprim-sulfamethoxazole is the agent of choice. Beta-lactamase inhibitors such as clavulanate are also active, and combination therapy may be indicated for certain serious infections due to S. maltophilia.
Insights
Stenotrophomonas maltophilia, a gram-negative bacterium, causes difficult-to-treat hospital-acquired infections, often in vulnerable patients. Trimethoprim-sulfamethoxazole is the preferred treatment, with combination therapy potentially beneficial for severe cases.
Area of Science:
- Microbiology
- Infectious Diseases
- Hospital Epidemiology
Background:
- Stenotrophomonas maltophilia is a ubiquitous Gram-negative bacterium.
- It is a common cause of hospital-acquired infections, particularly in immunocompromised individuals.
- Exposure often occurs via contaminated environmental water sources, leading to nosocomial outbreaks.
Purpose of the Study:
- To review the clinical significance of Stenotrophomonas maltophilia infections.
- To discuss the challenges in treating these infections due to antimicrobial resistance.
- To highlight effective therapeutic strategies.
Main Methods:
- Review of in vitro and clinical data on Stenotrophomonas maltophilia.
- Analysis of treatment outcomes for various infections.
- Evaluation of antimicrobial susceptibility patterns.
Main Results:
- S. maltophilia infections manifest as pneumonia, bacteremia, skin/soft tissue infections, UTIs, and endocarditis.
- The organism exhibits resistance to many common hospital-acquired infection agents.
- Trimethoprim-sulfamethoxazole demonstrated efficacy as the primary treatment agent.
- Beta-lactamase inhibitors like clavulanate showed activity.
Conclusions:
- Stenotrophomonas maltophilia poses a significant challenge in healthcare settings.
- Effective treatment relies on appropriate antimicrobial selection, with trimethoprim-sulfamethoxazole being the agent of choice.
- Combination therapy may be necessary for severe S. maltophilia infections.
Related Concept Videos
Fungal Phylum Microsporidia
Bacterial Phylum Tenericutes
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Acute Pyelonephritis II: Diagnostic Studies and Management
Rapid Identification of Pathogens
Bacterial Meningitis II: Pathophysiology